Juliane Lungershausen

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With <i>EGFR</i> Mutations

James Chih‐Hsin Yang, Vera Hirsh, Martin Schüler et al. · Journal of Clinical Oncology · 2013 · 319 citations

Advanced Lung Disease, Cancer Management, Pathology +19

The Economic Burden of Head and Neck Cancer: A Systematic Literature Review

Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen et al. · PharmacoEconomics · 2014 · 166 citations · Full text

Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting

C. Chouaïd, Jason Agulnik, Erdem Göker et al. · Journal of Thoracic Oncology · 2013 · 138 citations · Full text

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

Sarayut Lucien Geater, Chong‐Rui Xu, Caicun Zhou et al. · Journal of Thoracic Oncology · 2015 · 56 citations · Full text

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

James Chih‐Hsin Yang, Vera Hirsh, Martin Schüler et al. · PubMed · 2013 · 33 citations